Treatment - Page 22 of 472 Posts on Medivizor

Evaluating the effectiveness of a second autologous hematopoietic cell transplantation performed with stem cells obtained after previous transplantation in patients with relapsed multiple myeloma.

Posted by Medivizor on Jul 16, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness of salvage autologous hematopoietic cell transplantation (ASCT) performed with stem cells obtained after previous transplantation in patients with relapsed multiple myeloma (MM). The data showed that salvage ASCT performed with stem cells remobilized after previous transplantation is a good treatment...

Evaluating the effectiveness, durability, and safety of faricimab in patients with diabetic macular edema.

Posted by Medivizor on Jul 16, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the effectiveness, durability, and safety of faricimab (Vabysmo) for the treatment of patients with diabetic macular edema (DME). The data showed that faricimab with extended dosing up to every 16 weeks was safe and showed good vision gains and clinical improvements in these patients. Some background...

Evaluating the effectiveness and safety of darolutamide in combination with androgen deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer.

Posted by Medivizor on Jul 16, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) and docetaxel (Taxotere) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that darolutamide in combination with ADT and docetaxel significantly improved the overall...

Adding pembrolizumab before and after surgery for early triple-negative breast cancer

Posted by Medivizor on Jun 30, 2022 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate pembrolizumab (Keytruda) before and after surgery in patients with early triple-negative breast cancer (TNBC). This study concluded that the addition of pembrolizumab to chemotherapy before surgery and after surgery for TNBC improved the survival without complications from TNBC in these...

Aromatase inhibitors versus tamoxifen for premenopausal women with hormone positive early-stage breast cancer treated with ovarian suppression.

Posted by Medivizor on Jun 26, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness of aromatase inhibitors (AIs) versus tamoxifen (Nolvadex) for the treatment of premenopausal patients with estrogen receptor-positive (ER+) early-stage breast cancer (BC) treated with ovarian suppression. The data showed that AIs significantly reduced the risk of BC recurrence compared...

Evaluating the effectiveness and safety of isatuximab in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.

$Evaluating the effectiveness and safety of isatuximab in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.$

Posted by Medivizor on Jun 26, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of isatuximab (Sarclisa) in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (Decadron) (Pd) in previously treated patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that isatuximab plus Pd combination significantly improved the...

Evaluating the predictors of cure and overactive bladder syndrome after a mid-urethral sling procedure in women with stress urinary incontinence.

Posted by Medivizor on Jun 26, 2022 in Urinary incontinence | 0 comments

In a nutshell This study evaluated the factors that could predict the cure and overactive bladder (OAB) syndrome after a mid-urethral sling (MUS) procedure in women with stress urinary incontinence (SUI). The study found age and overactivity of the detrusor (bladder) before surgery were independent predictors of persisting/recurrent SUI. OAB before...

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Jun 26, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of actinium-225 [225Ac]-PSMA-617 (225AcPSMA) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 225AcPSMA was effective with manageable side effects for these patients. Some background Prostate cancer (PC) often grows in...

Evaluating the role of vitamin D supplementation in patients with breast cancer receiving doxorubicin chemotherapy.

Posted by Medivizor on Jun 26, 2022 in Breast cancer | 0 comments

In a nutshell The study investigated the effects of vitamin D (Vit D) supplementation in patients with early breast cancer receiving doxorubicin (DOX; Adriamycin)-based chemotherapy. The results showed that patients taking DOX plus Vit D had improved heart-related blood markers. Some background The main treatment for early...

Reviewing chemotherapy and hormonal therapy before prostate surgery in patients with prostate cancer

Posted by Medivizor on Jun 14, 2022 in Prostate cancer | 0 comments

In a nutshell The review investigated the effects of neoadjuvant chemo-hormonal therapy (NCHT; chemotherapy and hormonal therapy before surgery) in patients with prostate cancer (PCa). The results showed that compared to patients who received prostate surgery alone, NCHT before prostate surgery improved the oncological outcomes of these...

Comparing Retzius-sparing and conventional robot-assisted radical prostatectomy for men with localized prostate cancer

Posted by Medivizor on Jun 5, 2022 in Prostate cancer | 0 comments

In a nutshell This review compared the outcomes of 2 techniques for robotic-assisted radical prostatectomy (RARP; complete removal of the prostate gland using robotic arms): Retzius-sparing (RS)-RARP and conventional (C)-RARP in patients with localized prostate cancer (PCa). The analysis showed that RS-RARP was associated with improved urinary...

Extending therapy with aromatase inhibitors to 10 years in postmenopausal patients with hormone receptor-positive early-stage breast cancer.

Posted by Medivizor on Jun 5, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of extending treatment with letrozole (Femara), an aromatase inhibitor, to 10 years in postmenopausal patients with hormone receptor-positive (HR+) early-stage breast cancer (BC). The data showed that extending treatment with letrozole to 10 years significantly improved the...

Treatment Posts on Medivizor

Evaluating the effectiveness of a second autologous hematopoietic cell transplantation performed with stem cells obtained after previous transplantation in patients with relapsed multiple myeloma.

Evaluating the effectiveness, durability, and safety of faricimab in patients with diabetic macular edema.

Evaluating the effectiveness and safety of darolutamide in combination with androgen deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer.

Adding pembrolizumab before and after surgery for early triple-negative breast cancer

Aromatase inhibitors versus tamoxifen for premenopausal women with hormone positive early-stage breast cancer treated with ovarian suppression.

Evaluating the effectiveness and safety of isatuximab in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.

Evaluating the predictors of cure and overactive bladder syndrome after a mid-urethral sling procedure in women with stress urinary incontinence.

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the role of vitamin D supplementation in patients with breast cancer receiving doxorubicin chemotherapy.

Reviewing chemotherapy and hormonal therapy before prostate surgery in patients with prostate cancer

Comparing Retzius-sparing and conventional robot-assisted radical prostatectomy for men with localized prostate cancer

Extending therapy with aromatase inhibitors to 10 years in postmenopausal patients with hormone receptor-positive early-stage breast cancer.

Categories

Recent Posts

Archives

Treatment Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email